InvestorPlace just released an article titled “The 10 Top Stocks to Buy and Hold into 2021”
The article focuses on a long term framework and the avoidance of speculative companies that “have a one track mind” so to speak.
It talks about a “new normal” without the threat of a Covid-19 and mindful of their cash flow, Americans received a harsh lesson in health and protective measures that they may never forget.
It gives an “eclectic list of picks” but states that these companies have viable business that extend outside the cotona catalyst.
- 3M (NYSE: MMM)
- Home Depot (NYSE: HD)
- Costco (NASDAQ: COST)
- Amazon (NASDAQ: AMZN)
- Microsoft (NASDAQ: MSFT)
- Johnson & Johnson (NYSE: JNJ)
- GrubHub (NYSE: GRUB)
- K12 Inc. (NYSE: LRN)
- IBM (NYSE: IBM)
- Toyota (NYSE: TM)
Hers’s one that did not make this list probably because it focuses one thing. Making life better for those with Diabetes.
More than 100 million U.S. adults are now living with diabetes or prediabetes, according to a new report released by the Centers for Disease Control and Prevention (CDC).
Take a look at Glucose Health, Inc. (OTC Pink: GLUC). Glucose Health manufacturers nutritional beverages for the diabetic-adult nutrition consumer retail category under the registered trademark GLUCODOWN®.
Glucose Health, Inc. is an under-the-radar company whose GLUCODOWN® products are found in major national pharmacy chains including Walmart (NYSE: WMT), CVS Health (NYSE: CVS) and even online at Amazon.com (NASDAQ: AMZN) yet is still trading below a $20 million valuation.
The company’s flagship product GLUCODOWN® is infused with a special form of diabetic fiber demonstrated in more than 20 clinical studies to help maintain glucose (blood sugar) levels in a normal healthy range.
Glucose Health, Inc. (OTC Pink: GLUC) just announced unprecedented consumer demand and 2nd quarter fiscal 2020 sales. 2nd quarter fiscal 2020 revenues increased 186% compared to the 2nd quarter of fiscal 2019 – Q2 2020 revenues were just $7,140 short of tripling 2nd quarter 2019 revenues.
What are the revenues of this company going to look like when the latest GLUCODOWN® numbers are reported for Q3 and Q4?
Over the past 12 months, GLUC has seen a range of approximately $.20 – $1.90 per share and with only 12.5 million shares outstanding, GLUC could be the best value in the diabetic nutrition/medical foods space and should be on everybody’s watch list.
EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.